These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28196516)

  • 21. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France.
    Cuisset L; Jeru I; Dumont B; Fabre A; Cochet E; Le Bozec J; Delpech M; Amselem S; Touitou I;
    Ann Rheum Dis; 2011 Mar; 70(3):495-9. PubMed ID: 21109514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation.
    Alejandre N; Ruiz-Palacios A; García-Aparicio AM; Blanco-Kelly F; Bermúdez S; Fernández-Sanz G; Romero FI; Aróstegui JI; Ayuso C; Jiménez-Alfaro I; Herrero-Beaumont G; Sánchez-Pernaute O
    Rheumatology (Oxford); 2014 Jun; 53(6):1095-9. PubMed ID: 24501247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics.
    Lainka E; Neudorf U; Lohse P; Timmann C; Bielak M; Stojanov S; Huss K; von Kries R; Niehues T
    Klin Padiatr; 2010 Nov; 222(6):356-61. PubMed ID: 21058222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease.
    Fingerhutová Š; Fráňová J; Hlaváčková E; Jančová E; Procházková L; Beránková K; Tesařová M; Honsová E; Doležalová P
    Front Immunol; 2019; 10():802. PubMed ID: 31057541
    [No Abstract]   [Full Text] [Related]  

  • 25. Early-onset urticaria: a marker of cryopyrin-associated periodic syndrome.
    Sathishkumar D; Al-Abadi E; Nicklaus-Wollenteit I; Moss C; Hawkins PN; Gach JE
    Clin Exp Dermatol; 2017 Jul; 42(5):579-581. PubMed ID: 28512856
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early progression of atherosclerosis in children with chronic infantile neurological cutaneous and articular syndrome.
    Yamamura K; Takada H; Uike K; Nakashima Y; Hirata Y; Nagata H; Takimoto T; Ishimura M; Morihana E; Ohga S; Hara T
    Rheumatology (Oxford); 2014 Oct; 53(10):1783-7. PubMed ID: 24821850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization.
    Lasigliè D; Mensa-Vilaro A; Ferrera D; Caorsi R; Penco F; Santamaria G; Di Duca M; Amico G; Nakagawa K; Antonini F; Tommasini A; Consolini R; Insalaco A; Cattalini M; Obici L; Gallizzi R; Santarelli F; Del Zotto G; Severino M; Rubartelli A; Ravazzolo R; Martini A; Ceccherini I; Nishikomori R; Gattorno M; Arostegui JI; Borghini S
    J Rheumatol; 2017 Nov; 44(11):1667-1673. PubMed ID: 28916543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
    Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
    Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement.
    Kolivras A; Theunis A; Ferster A; Lipsker D; Sass U; Dussart A; André J
    J Cutan Pathol; 2011 Feb; 38(2):202-8. PubMed ID: 21062341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome.
    Enríquez R; Sirvent AE; Padilla S; Noguera-Pons R; Andrada E; Ardoy F; Millán I; Amorós F
    Ren Fail; 2013; 35(5):738-41. PubMed ID: 23650909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and clinical features of cryopyrin-associated periodic syndromes in Turkish children.
    Eroglu FK; Kasapcopur O; Beşbaş N; Ozaltin F; Bilginer Y; Barut K; Mensa-Vilaro A; Nakagawa K; Heike T; Nishikomori R; Arostegui J; Ozen S
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S115-S120. PubMed ID: 27191192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.
    Elmi AA; Wynne K; Cheng IL; Eleftheriou D; Lachmann HJ; Hawkins PN; Brogan P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):36. PubMed ID: 31287007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cryopyrin-associated periodic syndromes and the eye.
    Oberg TJ; Vitale AT; Hoffman RO; Bohnsack JF; Warner JE
    Ocul Immunol Inflamm; 2013 Aug; 21(4):306-9. PubMed ID: 23662681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum amyloid protein A concentration in cryopyrin-associated periodic syndromes patients treated with interleukin-1 beta antagonist.
    Pastore S; Paloni G; Caorsi R; Ronfani L; Taddio A; Lepore L;
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S63-6. PubMed ID: 25069027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Papilledema as a possible key sign for diagnosis of cryopyrin-associated periodic syndromes (CAPS): A case report.
    Arteaga Henríquez C; Arteaga Henríquez M; Álava Cruz C; Hernández León CN; Díaz-Flores Estévez FM; Doble Rivera D
    Arch Soc Esp Oftalmol (Engl Ed); 2023 Jun; 98(6):360-364. PubMed ID: 37121396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
    Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
    Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ozen S; Tyrrell PN; Kone-Paut I; Goldbach-Mansky R; Lachmann H; Blank N; Hoffman HM; Weissbarth-Riedel E; Hugle B; Kallinich T; Gattorno M; Gul A; Ter Haar N; Oswald M; Dedeoglu F; Cantarini L; Benseler SM
    Ann Rheum Dis; 2017 Jun; 76(6):942-947. PubMed ID: 27707729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.